Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

SYDNEY, Feb. 16, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...

A short course of darolutamide (Nubeqa) enhanced the imaging signal of prostate-specific membrane antigen (PSMA)-PET in a ...

TRE-515 has received FDA fast track designation for treating PSMA-positive mCRPC, aiming to accelerate its development and availability. The drug is being tested in combination with Pluvicto, a ...

India, April 2 -- Men with early-stage metastatic prostate cancer may soon be able to postpone the debilitating side effects ...

The trial design for ARASTEP is highlighted in the following schema: Two special considerations for ARASTEP are that all patients have maximally treated pelvic disease and that metastasis directed ...

A randomized study in 58 men with limited metastatic prostate cancer found that PSMA therapy postponed the need for hormone ...

The prospective, multi-center phase 3 PRIMARY randomized trial tested the additive diagnostic value of PSMA PET imaging in high-risk men with negative or equivocal MRI in the diagnosis of significant ...

Surgery patients staged with PSMA-PET appear to have a lower risk of early BCR than those staged with conventional imaging. Early oncologic outcomes after radical prostatectomy (RP) for very high risk ...

Basel, Switzerland / Munich, Germany, January 26, 2026 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that U.S ...